Peptide Impurity Profiling — Truncations, Deletions, Modifications, and Where They Come From

Every peptide HPLC trace has the main peak — and then it has shoulders, small early-eluting peaks, late-eluting tails, and an occasional satellite peak at exactly 1.0% area. These are not random noise. They are specific impurities with specific chemistry, each pointing to a specific stage of the synthesis where the issue arose. Reading the impurity profile is a separate skill from reading the main peak purity, and it tells the buyer (and the synthesis team) more about what they actually have in the vial than the purity number does. This Note maps the major impurity classes for SPPS peptides, explains what each indicates, and frames how ICH Q3A applies in the research-grade context.

The four major impurity classes

Solid-phase peptide synthesis (SPPS) generates a characteristic family of impurities. Most appear in roughly the same retention-time region (usually within ±15% of the main peak) and most have characteristic mass-spec signatures that allow assignment without dedicated trapping experiments.

### Truncations

The most common class. A truncation peptide is the labelled sequence missing one or more residues from the N-terminus because the corresponding coupling cycle failed. The molecule that comes off the resin is the partial sequence that was successfully coupled up to (but not including) the failure point, then capped against further extension.

ESI-MS signature: mass shift downward by the residue mass(es) of the missed coupling(s). A 25-mer missing a Leu at position 5 shows up at the labelled mass minus 113.084 Da (Leu residue mass).

HPLC signature: typically elutes earlier than the main peak (shorter, less hydrophobic). Multiple truncation products eluting close together create the early-shoulder "fuzz" pattern on the chromatogram.

What it indicates about the synthesis: a specific coupling cycle had reduced efficiency. Cause is usually an aggregation event of the growing chain (the resin becomes poorly solvated at that point) or a sluggish residue (His, His-Pro, Pro-Pro junctions). Per-cycle coupling efficiency in well-run SPPS is 99.0–99.8%; even 99.5% per cycle on a 25-mer leaves ~12% accumulated yield loss, a fraction of which appears as discrete truncation peaks.

### Deletions

Distinct from truncations: a deletion peptide is missing one (or more) internal residues, with the rest of the sequence intact. The molecule is the labelled sequence with one residue snipped out.

ESI-MS signature: same kind of mass shift as truncation but the gap is internal rather than at the N-terminus. Distinguishing truncation from deletion by mass alone is not always possible — the products have similar masses if the missed residue happens to be the second-to-N-terminal one in either case.

HPLC signature: usually a satellite peak closely co-eluting with the main peak (the molecule differs from the labelled by only one residue, so retention time is close).

What it indicates: typically a single double-coupling cycle where the protected amine on the new residue was not fully removed before the next coupling, so the next residue coupled to the wrong amine. Cleaner SPPS reduces this; the impurity is generally an early indicator that coupling chemistry needs tuning.

### Modifications (incomplete deprotection / capping artifacts)

A class of impurities where the released peptide carries an unwanted chemical group from incomplete removal of side-chain protecting groups, or from a stable adduct that formed during the cleavage step.

Common modifications: - Pyroglutamate (pGlu) — forms from N-terminal Gln or Glu via intramolecular cyclization. Mass shift is −17 Da (loss of NH₃) from Gln, or −18 Da (loss of H₂O) from Glu. Eluttes earlier than the main peak. - Residual t-butyl — incomplete deprotection of Asp, Glu, Ser, Thr, or Tyr side chains. Mass shift +56 Da per residual t-Bu group. - Residual Fmoc — incomplete N-terminal Fmoc removal on the final residue. Mass shift +222 Da. Indicates the N-terminal deprotection was missed entirely, usually a workflow error not a chemistry issue. - Alkylation by scavengers — leftover scavenger molecules (triisopropylsilane, water, thioanisole) that quench reactive carbocations during cleavage can leave covalent adducts at specific positions. Mass shifts are scavenger-specific (e.g. +56 Da for t-Bu+, +90 Da for trityl+). - Oxidation — Met → Met-sulfoxide adds +16 Da; Cys oxidation states add +16/+32/+48 Da. These can be cleavage-related or storage-related and the distinction matters for assigning root cause.

HPLC signature: each modification has a characteristic retention shift. Met-sulfoxide is typically 1-3 min earlier than the parent peak; residual Fmoc is much later (more hydrophobic) than the parent.

### Diastereomers / racemization

A subset of side reactions during coupling (especially of Cys, His, and Ser/Thr) leads to D-isomer formation at one residue while the rest of the sequence remains L. The product has the same mass as the labelled peptide but different stereochemistry.

ESI-MS signature: identical to labelled mass. Mass spec alone cannot detect this.

HPLC signature: on a standard C18 column, the diastereomer often (but not always) elutes as a satellite peak very close to the main peak. On a chiral stationary phase or after acid hydrolysis followed by chiral amino-acid analysis, the diastereomer is unambiguous.

What it indicates: usually a coupling reagent issue or a sequence-specific susceptible residue. Cys-containing sequences are the most common; Cys can racemize during activation, especially with HBTU at long activation times.

How impurity profile fits the lot release

The standard release packet for a research-grade peptide reports: - Main peak purity by RP-HPLC at 214 nm (e.g. ≥ 98.5%) - ESI-MS measured mass of the main peak (e.g. observed 1234.5 Da, theoretical 1234.6 Da, Δ −0.1 Da) - Amino acid analysis composition vs theoretical

This does not directly identify the impurities — it only tells you how much non-main-peak material is present and that the main peak mass agrees. For a buyer planning bioassay work where impurities could confound results, an impurity-specific characterization is the add-on:

LC-HRMS impurity ID — separates impurities and assigns each by high-resolution accurate mass + characteristic retention-time shift. A modern application of this is described in [Waters' compliance-ready peptide impurity workflow](https://www.waters.com/content/dam/waters/en/app-notes/2018/720006367/720006367-en.pdf) and the [LC-HRMS review at PMC4406950](https://pmc.ncbi.nlm.nih.gov/articles/PMC4406950/).

The output is an impurity table: each impurity assigned to a class (truncation at position N / deletion of residue M / pyroglutamate / residual Fmoc / etc.) with the mass shift and the area percent.

How ICH Q3A applies to research-grade peptides

ICH Q3A(R2) defines impurity reporting, identification, and qualification thresholds for new drug substances. Two thresholds matter operationally:

• Reporting threshold (typically 0.05% for ≤ 2 g/day max daily dose): impurities above this must be reported on the COA
• Identification threshold (typically 0.10% – 0.15%): impurities above this must be identified (i.e. assigned to a chemical structure)

These are written for pharmaceutical drug substances entering regulatory filings — not strictly applicable to research-grade peptides. But the framework is useful as a buyer's expectation:

What Lyochem ships and what's on request

Every Lyochem reference-grade lot ships with: - RP-HPLC at 214 nm trace + integrated main-peak purity (release spec ≥ 98.5%) - ESI-MS observed monoisotopic mass + Δ to theoretical - AAA confirming composition

On request and noted on the COA: - LC-HRMS impurity ID with per-impurity mass shift, class assignment (truncation / deletion / modification / racemization), and area percent for any impurity ≥ 0.5% - Specific impurity assays for known-vulnerable sequences (Met-sulfoxide quantitation for Met-containing peptides; Asp / iso-Asp split for Asn/Asp-Gly-containing sequences) - Inter-lot impurity profile comparison for buyers running long-duration studies — same impurities at same percentages across lots is the underrated stability signal

For most research projects, the standard release packet is fit-for-purpose. For projects where a 0.3% impurity in a bioassay could materially shift the result, the LC-HRMS impurity ID is the add-on to request explicitly. The cost is modest compared to running a confounded study to completion.

Reading shoulders on YOUR chromatogram

If the lot HPLC trace you received shows a shoulder, an unexpected satellite peak, or a tail that doesn't look like other lots of the same sequence: - Note the retention-time difference from the main peak (earlier = less hydrophobic; later = more hydrophobic / residual protecting group) - Note the area percent - Send the trace + the lot reference to your supplier contact and ask "what impurity class is this?" - The answer should be specific (truncation at position N / Met-sulfoxide / residual t-Bu) — not "minor impurity" or "within spec"

A supplier who can't tell you what the small peaks are doesn't have the LC-HRMS workflow to back the purity claim. That's a more useful sourcing signal than the purity number itself.